Arthritis & Rheumatism, Volume 62,
November 2010 Abstract Supplement
Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Atlanta, Georgia November 6-11, 2010.
Extracellular HMGB1 Is Increased in Patients with Behcet's Disease with Intestinal Involvement.
Ahn2, Joong Kyong, Lee3, You Sun, Park4, Eun-Jung, Hwang4, Ji-Won, Oh4, Ji-Min, Lee4, Jaejoon, Jeon1, Chan-Hong
Bucheon Hospital, Soonchunhyang University College of Medicine
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
Masan Samsung Hospital, Sungkyunkwan University School of Medicine
Samsung Medical Center, Sungkyunkwan University School of Medicine
Behcet's disease (BD) is a chronic multisystemic inflammatory disorder of unknown etiology consisting of orogenital ulceration, ocular inflammation, and skin lesions. HMGB1 (High-Mobility Group Box 1 protein) has been demonstrated to play an important role in chronic inflammatory diseases including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory myositis. HMGB1 is a crucial cytokine that mediates the response to infection, injury and inflammation. HMGB1 activates macrophages and monocytes to release proinflammatory cytokines, upregulates endothelial adhesion molecules, and stimulates epithelial cell barrier failure. We performed this study to investigate the association between extracellular HMGB1 expression and disease activity and clinical features of Behcet's disease.
Extracellular HMGB1 expression from the sera of 42 BD patients and age- and sex-matched 22 healthy controls (HC) was measured using ELISA.
According to the activity criteria based on clinical manifestation at the time of study, 42 patients with BD comprised 25 active and 15 inactive patients with mean age of 47 years (range 2265 years). The HMGB1 concentration was significantly increased in BD patients compared to HC (78.70±20.22 vs. 10.79±1.90 ng/ml, p=0.002). In addition, HMGB1 concentration was significantly elevated in patients with intestinal involvement compared to those without (179.61±67.95 vs. 61.89±19.81, p=0.04). Patients with vascular involvement showed decreased trend of serum HMGB1 expression compared to those without vascular involvement (36.79±12.63 vs. 95.47±27.41 ng/ml, p=0.059). There was no significant association between HMGB1 concentration and clinical manifestation, including genital ulcer, erythema nodosum, ocular involvement or musculoskeletal symptoms. No significant difference in the serum HMGB1 level was found between inactive and active BD patients (58.78±18.46 vs. 92.26±31.63 ng/ml, p=0.367). No significant correlation was found between HMGB1 concentration and leukocyte counts, ESR, or CRP.
This is the first study to evaluate the expression of HMGB1 in Behcet's disease. An important finding in our study is that extracellular HMGB1 concentrations are significantly increased in BD patients compared to HC, and are significantly increased in the sera of BD patients with intestinal involvement compared to those without intestinal involvement. These results suggest that extracellular HMGB1 may play an important role in the pathogenesis of BD.
To cite this abstract, please use the following information:
Ahn, Joong Kyong, Lee, You Sun, Park, Eun-Jung, Hwang, Ji-Won, Oh, Ji-Min, Lee, Jaejoon, et al; Extracellular HMGB1 Is Increased in Patients with Behcet's Disease with Intestinal Involvement. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :1297